{"Title": ["iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "3 Biotech Quick Picks to Invest $5,000 This Week", "Could Illumina Be a Millionaire-Maker Stock?", "IBB, ILMN, SGEN, ALXN: ETF Inflow Alert", "Nasdaq 100 Movers: CSGP, ROST", "Noteworthy Wednesday Option Activity: GILD, ILMN, ATVI", "Natera, Illumina Settle Patent Dispute - Quick Facts", "Could Exact Sciences Be a Millionaire-Maker Stock?", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "China's BGI gets Australian foothold through mass coronavirus test delivery", "BUZZ-U.S. STOCKS ON THE MOVE-Cornerstone Building, Aerpio Pharma, J.C. Penney", "UK researchers try to crack genetic riddle of COVID-19", "UK researchers try to crack genetic riddle of COVID-19", "Notable Tuesday Option Activity: BLK, GS, ILMN", "Adaptive Biotechnologies and Microsoft Announce New Study of COVID-19 Immune Response", "China's BGI gets Australian foothold through mass coronavirus test delivery", "Notable ETF Outflow Detected - IBB, ILMN, ALXN, INCY", "Illumina Inc (ILMN) Q1 2020 Earnings Call Transcript", "Illumina Inc. Q1 adjusted earnings Beat Estimates", "ILMN June 12th Options Begin Trading", "Better Buy: Illumina vs. Adaptive Biotechnologies", "How These 15 Stock Suggestions Fared Against the Market", "Illumina Reaches Analyst Target Price", "1 Recent IPO to Add to Your Watch List", "BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Medigus, Aemetis", "Illumina Inc (ILMN) Q1 2020 Earnings Call Transcript", "Why Is Everyone Talking About Guardant Health Stock?", "Stocks to Watch in April", "First Week of May 22nd Options Trading For Illumina (ILMN)", "Why Illumina Shares Rose 2.8% in March", "Should You Buy Illumina Stock During the Coronavirus Bear Market?", "2 Top Stocks That Aren't On Wall Street's Radar", "ILMN Crosses Above Key Moving Average Level", "IBB, VRTX, BIIB, ILMN: ETF Outflow Alert", "iShares Nasdaq Biotechnology ETF Experiences Big Inflow", "Microsoft and Adaptive Biotechnologies' Immune System Partnership Takes on Coronavirus", "6 Med-Tech and Medical-Device Stocks to Buy", "Notable Friday Option Activity: ILMN, DOCU, ROKU", "Illumina Becomes Oversold (ILMN)", "First Week of April 9th Options Trading For Illumina (ILMN)", "2 Medical Device Companies Trading at Bargain Prices", "Where Will Illumina Be in 1 Year?", "Illumina Adds Former FDA Commissioner Scott Gottlieb to Its Board of Directors", "Is Illumina Stock a Buy?", "Why Illumina Stock Declined by 11% in January", "Could Guardant Health Be a Millionaire-Maker Stock?", "Oversold Conditions For Illumina (ILMN)", "Thursday Sector Laggards: Healthcare, Materials", "Validea Peter Lynch Strategy Daily Upgrade Report - 2/28/2020", "The 3 Most Important Things to Know About Illumina's Q4 Results"], "Elapsed Time": ["50 MINUTES AGO", "3 DAYS AGO", "4 DAYS AGO", "MAY 26, 2020", "MAY 21, 2020", "MAY 20, 2020", "MAY 18, 2020", "MAY 17, 2020", "50 MINUTES AGO", "MAY 14, 2020", "MAY 13, 2020", "MAY 13, 2020", "MAY 12, 2020", "MAY 12, 2020", "MAY 6, 2020", "MAY 6, 2020", "MAY 15, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 28, 2020", "APR 20, 2020", "APR 17, 2020", "MAY 1, 2020", "APR 30, 2020", "APR 11, 2020", "APR 8, 2020", "APR 7, 2020", "APR 5, 2020", "APR 5, 2020", "APR 4, 2020", "APR 16, 2020", "MAR 31, 2020", "MAR 23, 2020", "MAR 20, 2020", "MAR 19, 2020", "MAR 13, 2020", "MAR 12, 2020", "MAR 6, 2020", "APR 1, 2020", "FEB 19, 2020", "FEB 7, 2020", "FEB 5, 2020", "FEB 3, 2020", "FEB 2, 2020", "JAN 30, 2020", "JAN 30, 2020", "FEB 28, 2020", "JAN 30, 2020"], "Published Date": ["Jun 4, 2020 10:51AM EDT", "Jun 1, 2020 11:00AM EDT", "May 31, 2020 6:44AM EDT", "May 26, 2020 10:52AM EDT", "May 21, 2020 10:21AM EDT", "May 20, 2020 3:26PM EDT", "May 18, 2020 9:16AM EDT", "May 17, 2020 6:46AM EDT", "Jun 4, 2020 10:51AM EDT", "May 14, 2020 3:49AM EDT", "May 13, 2020 11:26AM EDT", "May 13, 2020 2:55AM EDT", "May 12, 2020 7:00PM EDT", "May 12, 2020 1:37PM EDT", "May 6, 2020 12:10PM EDT", "May 6, 2020 3:45AM EDT", "May 15, 2020 10:51AM EDT", "Apr 30, 2020 9:30PM EDT", "Apr 30, 2020 5:08PM EDT", "Apr 30, 2020 11:37AM EDT", "Apr 30, 2020 6:39AM EDT", "Apr 28, 2020 12:44PM EDT", "Apr 20, 2020 8:42AM EDT", "Apr 17, 2020 6:56AM EDT", "May 1, 2020 1:18PM EDT", "Apr 30, 2020 9:30PM EDT", "Apr 11, 2020 7:34AM EDT", "Apr 8, 2020 6:08AM EDT", "Apr 7, 2020 10:40AM EDT", "Apr 5, 2020 10:20AM EDT", "Apr 5, 2020 7:40AM EDT", "Apr 4, 2020 7:39AM EDT", "Apr 16, 2020 11:26AM EDT", "Mar 31, 2020 10:48AM EDT", "Mar 23, 2020 10:52AM EDT", "Mar 20, 2020 5:33PM EDT", "Mar 19, 2020 4:38AM EDT", "Mar 13, 2020 3:20PM EDT", "Mar 12, 2020 12:38PM EDT", "Mar 6, 2020 10:41AM EST", "Apr 1, 2020 8:35AM EDT", "Feb 19, 2020 11:15AM EST", "Feb 7, 2020 5:25PM EST", "Feb 5, 2020 7:42AM EST", "Feb 3, 2020 10:07PM EST", "Feb 2, 2020 9:04AM EST", "Jan 30, 2020 4:28PM EST", "Jan 30, 2020 2:42PM EST", "Feb 28, 2020 10:00AM EST", "Jan 30, 2020 7:00AM EST"], "Link": ["https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2020-06-04", "https://www.nasdaq.com/articles/3-biotech-quick-picks-to-invest-%245000-this-week-2020-06-01", "https://www.nasdaq.com/articles/could-illumina-be-a-millionaire-maker-stock-2020-05-31", "https://www.nasdaq.com/articles/ibb-ilmn-sgen-alxn%3A-etf-inflow-alert-2020-05-26", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-csgp-rost-2020-05-21", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-gild-ilmn-atvi-2020-05-20", "https://www.nasdaq.com/articles/natera-illumina-settle-patent-dispute-quick-facts-2020-05-18", "https://www.nasdaq.com/articles/could-exact-sciences-be-a-millionaire-maker-stock-2020-05-17", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2020-06-04", "https://www.nasdaq.com/articles/chinas-bgi-gets-australian-foothold-through-mass-coronavirus-test-delivery-2020-05-14", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-cornerstone-building-aerpio-pharma-j.c.-penney-2020-05-13", "https://www.nasdaq.com/articles/uk-researchers-try-to-crack-genetic-riddle-of-covid-19-2020-05-13", "https://www.nasdaq.com/articles/uk-researchers-try-to-crack-genetic-riddle-of-covid-19-2020-05-12", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-blk-gs-ilmn-2020-05-12", "https://www.nasdaq.com/articles/adaptive-biotechnologies-and-microsoft-announce-new-study-of-covid-19-immune-response-2020", "https://www.nasdaq.com/articles/chinas-bgi-gets-australian-foothold-through-mass-coronavirus-test-delivery-2020-05-06", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-ilmn-alxn-incy-2020-05-15", "https://www.nasdaq.com/articles/illumina-inc-ilmn-q1-2020-earnings-call-transcript-2020-05-01", "https://www.nasdaq.com/articles/illumina-inc.-q1-adjusted-earnings-beat-estimates-2020-04-30", "https://www.nasdaq.com/articles/ilmn-june-12th-options-begin-trading-2020-04-30", "https://www.nasdaq.com/articles/better-buy%3A-illumina-vs.-adaptive-biotechnologies-2020-04-30", "https://www.nasdaq.com/articles/how-these-15-stock-suggestions-fared-against-the-market-2020-04-28", "https://www.nasdaq.com/articles/illumina-reaches-analyst-target-price-2020-04-20", "https://www.nasdaq.com/articles/1-recent-ipo-to-add-to-your-watch-list-2020-04-17", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-medigus-aemetis-2020-05-01", "https://www.nasdaq.com/articles/illumina-inc-ilmn-q1-2020-earnings-call-transcript-2020-05-01", "https://www.nasdaq.com/articles/why-is-everyone-talking-about-guardant-health-stock-2020-04-11", "https://www.nasdaq.com/articles/stocks-to-watch-in-april-2020-04-08", "https://www.nasdaq.com/articles/first-week-of-may-22nd-options-trading-for-illumina-ilmn-2020-04-07", "https://www.nasdaq.com/articles/why-illumina-shares-rose-2.8-in-march-2020-04-05", "https://www.nasdaq.com/articles/should-you-buy-illumina-stock-during-the-coronavirus-bear-market-2020-04-05", "https://www.nasdaq.com/articles/2-top-stocks-that-arent-on-wall-streets-radar-2020-04-04", "https://www.nasdaq.com/articles/ilmn-crosses-above-key-moving-average-level-2020-04-16", "https://www.nasdaq.com/articles/ibb-vrtx-biib-ilmn%3A-etf-outflow-alert-2020-03-31", "https://www.nasdaq.com/articles/ishares-nasdaq-biotechnology-etf-experiences-big-inflow-2020-03-23", "https://www.nasdaq.com/articles/microsoft-and-adaptive-biotechnologies-immune-system-partnership-takes-on-coronavirus-2020", "https://www.nasdaq.com/articles/6-med-tech-and-medical-device-stocks-to-buy-2020-03-19", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-ilmn-docu-roku-2020-03-13", "https://www.nasdaq.com/articles/illumina-becomes-oversold-ilmn-2020-03-12", "https://www.nasdaq.com/articles/first-week-of-april-9th-options-trading-for-illumina-ilmn-2020-03-06", "https://www.nasdaq.com/articles/2-medical-device-companies-trading-at-bargain-prices-2020-04-01", "https://www.nasdaq.com/articles/where-will-illumina-be-in-1-year-2020-02-19", "https://www.nasdaq.com/articles/illumina-adds-former-fda-commissioner-scott-gottlieb-to-its-board-of-directors-2020-02-07", "https://www.nasdaq.com/articles/is-illumina-stock-a-buy-2020-02-05", "https://www.nasdaq.com/articles/why-illumina-stock-declined-by-11-in-january-2020-02-04", "https://www.nasdaq.com/articles/could-guardant-health-be-a-millionaire-maker-stock-2020-02-02", "https://www.nasdaq.com/articles/oversold-conditions-for-illumina-ilmn-2020-01-30", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-healthcare-materials-2020-01-30", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-2-28-2020-2020-02-28", "https://www.nasdaq.com/articles/the-3-most-important-things-to-know-about-illuminas-q4-results-2020-01-30"], "Content": ["Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF (Symbol: IBB) where we have detected an approximate $185.7 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 65,200,000 to 66,600,000).  Among the largest underlying components of IBB, in trading today Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 0.3%, Biogen Inc (Symbol: BIIB) is down about 0.3%, and Illumina Inc (Symbol: ILMN) is up by about 0.4%. For a complete list of holdings, visit the IBB Holdings page \u00bb \n\nThe chart below shows the one year price performance of IBB, versus its 200 day moving average:\n   \n\nEND", "Building a balanced portfolio of healthcare stocks requires investing in safer and more mature companies as well as riskier upstarts to drive long-term growth. Between Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), and Vir Biotechnology (NASDAQ: VIR), there's something here for every investor.END", "Like peers in the life sciences industry, Illumina (NASDAQ: ILMN) hasn't been immune to the coronavirus outbreak. Shares of the genome sequencing giant fell\u00a0as much as 37% earlier this year as the outbreak led to a general market crash.The crisis also hurt revenue: The maker of genome sequencing systems saw a slowdown in business as some customers temporarily closed labs, and as a result, delayed testing using Illumina's tools. Illumina isn't offering an outlook on the months ahead because the duration of the coronavirus crisis isn't clear.END", "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF (Symbol: IBB) where we have detected an approximate $220.0 million dollar inflow -- that's a 2.6% increase week over week in outstanding units (from 63,750,000 to 65,400,000).  Among the largest underlying components of IBB, in trading today Illumina Inc (Symbol: ILMN) is up about 0.8%, Seattle Genetics Inc (Symbol: SGEN) is up about 0.9%, and Alexion Pharmaceuticals Inc. (Symbol: ALXN) is higher by about 2.7%. For a complete list of holdings, visit the IBB Holdings page \u00bb \n\nThe chart below shows the one year price performance of IBB, versus its 200 day moving average:\n   \n\nEND", "\nIn early trading on Thursday, shares of Ross Stores topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.7%.  Year to date, Ross Stores has lost about 15.9% of its value.\n\nAnd the worst performing Nasdaq 100 component thus far on the day is CoStar Group, trading down 3.7%.  CoStar Group is showing a gain of 9.2% looking at the year to date performance.\n\nTwo other components making moves today are Illumina, trading down 2.8%, and United Airlines Holdings, trading up 3.4% on the day.\n\n \n\n\n\n\n\n\n\nVIDEO: Nasdaq 100 Movers: CSGP, ROST\nEND", "Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Gilead Sciences Inc (Symbol: GILD), where a total of 99,052 contracts have traded so far, representing approximately 9.9 million underlying shares.  That amounts to about 44.9% of GILD's average daily trading volume over the past month of 22.1 million shares.  Especially high volume was seen for the $75 strike call option expiring June 05, 2020, with 22,693 contracts trading so far today, representing approximately 2.3 million underlying shares of GILD.  Below is a chart showing GILD's trailing twelve month trading history, with the $75 strike highlighted in orange:\n\nEND", "(RTTNews) - Cell-free DNA testing company Natera, Inc. (NTRA) and sequencing platform Illumina Inc. (ILMN) announced Monday that they have settled their patent infringement action concerning Illumina's U.S. Patent No. 9,493,831 and Natera's U.S. Patent No. 8,682,592.The settlement resolves and dismisses all of the claims in the Action, including claims that relate to non-invasive prenatal testing, occurring before the settlement date. Natera will receive a license to Illumina's intellectual property for use in NIPT using the Illumina sequencing platform. Terms of the settlement benefit both parties, and the supply agreement has been extended until 2030. Additionally, Natera has granted Illumina a non-exclusive license to Natera's Patent family. The license is limited to Illumina's current technology used for massively parallel sequencing in the fields of NIPT and PGS/PGD.Terms of the settlement are included in the Form 8-K filed May 11, 2020 by Natera with the U.S. Securities & Exchange Commission. END", "Cancer diagnostic leader Exact Sciences (NASDAQ: EXAS)\u00a0isn't having the best of years, and not just because of the COVID-19 pandemic. In February, the company announced it was selling approximately $1 billion in senior convertible notes to raise money. These notes will carry an annual interest rate of 0.3750% and will mature in 2028.Investors were not thrilled at the prospect of Exact Sciences taking on more debt, and this round of fundraising probably contributed to the company's stock dropping by more than 40% in the first quarter. Still, Exact Sciences has since rebounded along with the broader market. As of this writing, the company's shares are down 6% year to date, while the S&P 500's loss stands at 12.2% over the same period.It's difficult to assess how Exact Sciences will perform within the next few months. We have yet to see the full economic impact of the pandemic, and the company's stock could go either way.\u00a0Looking further down the road, though, Exact Sciences boasts several exciting opportunities that could help its stock perform well for many years to come. But could this healthcare company turn ordinary investors into millionaires?\u00a0END", "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF (Symbol: IBB) where we have detected an approximate $185.7 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 65,200,000 to 66,600,000).  Among the largest underlying components of IBB, in trading today Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 0.3%, Biogen Inc (Symbol: BIIB) is down about 0.3%, and Illumina Inc (Symbol: ILMN) is up by about 0.4%. For a complete list of holdings, visit the IBB Holdings page \u00bb \n\nThe chart below shows the one year price performance of IBB, versus its 200 day moving average:\n   \n\nEND", "By Kirsty NeedhamSYDNEY, May 6 (Reuters) - Australia says its purchase of 10 million coronavirus test kits from Chinese genomics company BGI will not risk patient privacy, as researchers hope for greater price competition in a biotech market dominated by a U.S rival.The deal was struck even as relations between Australia and China have been strained by Australia's call for a global enquiry into the coronavirus outbreak, which China has framed as a U.S.-led attempt to blame it for the pandemic. BGI \u2013 Beijing Genomics Institute - has grown into one of the world's largest genomics companies in the two decades since it worked on the Human Genome Project. It has one lab in Australia and had been seeking to expand its genome sequencing services.BGI, whose BGI Genomics Co 300676.SZ is listed on the Shenzhen stock exchange, was named as having \"evident links\" to the Chinese government in a U.S. Trade Office report into Chinese technology transfer practices that was used to justify the U.S. imposition of tariffs on Chinese exports.END", "Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: http://tmsnrt.rs/2ggOmBiThe Morning News Call newsletter: http://tmsnrt.rs/2fwPLThU.The S&P 500 and Dow slipped on Wednesday as Federal Reserve Chairman Jerome Powell warned of an extended period of weak growth and stagnant incomes, while he also dismissed speculation over negative interest rates. .NAt 11:11 ET, the Dow Jones Industrial Average .DJI was down 0.93% at 23,543.61. The S&P 500 .SPX was down 0.41% at 2,858.26 and the Nasdaq Composite .IXIC was down 0.07% at 8,995.922.   The top three S&P 500 .PG.INX percentage gainers:  ** BlackRock Inc <BLK.N>, up 4.5%  ** Regeneron Pharmaceuticals Inc <REGN.O>, up 3.9%  ** Illumina Inc <ILMN.O>, up 3.5%   The top three S&P 500 .PL.INX percentage losers:  ** Coty Inc <COTY.N>, down 12.4%  ** SL Green Realty Corp <SLG.N>, down 10.5%  ** Under Armour Inc <UAA.N>, down 8.3%   The top three NYSE .PG.N percentage gainers:  ** SIFCO Industries Inc <SIF.N>, up 98.4%  ** United Natural Foods Inc <UNFI.N>, up 38.6%  ** PGT Innovations Inc <PGTI.N>, up 18.1%   The top three NYSE .PL.N percentage losers:  ** 8X8 Inc  <EGHT.N>, down 20.9%  ** FTS International Inc <FTSI.N>, down 19.1%  ** Container Store Group Inc <TCS.N>, down 17.1%   The top three Nasdaq .PG.O percentage gainers:  ** Esports Entertainment Group Inc <GMBL.O>, up 50.5%  ** Aviat Networks Inc <AVNW.O>, up 32.6%  ** Progyny Inc <PGNY.O>, up 30.4%   The top three Nasdaq .PL.O percentage losers:  ** Varex Imaging Corp <VREX.O>, down 29.7%  ** Infinera Corp <INFN.O>, down 21.2%  ** Medalist Diversified REIT Inc <MDRRP.O>, down 18.9%     ** Aviat Networks Inc AVNW.O: up 32.6%END", "By Guy FaulconbridgeLONDON, May 13 (Reuters) - British researchers will study the genes of thousands of ill COVID-19 patients to try to crack one of the most puzzling riddles of the novel coronavirus: why does it kill some people but give others not even a mild headache?Researchers from across the United Kingdom will sequence the genetic code of people who fell critically ill with COVID-19 and compare their genomes with those who were mildly ill or not ill at all.The hunt for the specific genes that could cause a predisposition to getting ill with COVID-19 will involve up to 20,000 people currently or previously in hospital intensive care with COVID-19 and about 15,000 people with mild symptoms.Scientists caution that their knowledge of the novel coronavirus, which emerged in China last year, is still modest though they say it is striking how it can be so deadly for some but so mild for others.END", "By Guy FaulconbridgeLONDON, May 13 (Reuters) - British researchers will study the genes of thousands of ill COVID-19 patients to try to crack one of the most puzzling riddles of the novel coronavirus: why does it kill some people but give others not even a mild headache?Researchers from across the United Kingdom will sequence the genetic code of people who fell critically ill with COVID-19 and compare their genomes with those who were mildly ill or not ill at all.The hunt for the specific genes that could cause a predisposition to getting ill with COVID-19 will involve up to 20,000 people currently or previously in hospital intensive care with COVID-19 and about 15,000 people with mild symptoms.Scientists caution that their knowledge of the novel coronavirus, which emerged in China last year, is still modest though they say it is striking how it can be so deadly for some but so mild for others.END", "Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Blackrock Inc (Symbol: BLK), where a total of 6,048 contracts have traded so far, representing approximately 604,800 underlying shares.  That amounts to about 93.5% of BLK's average daily trading volume over the past month of 646,950 shares.  Particularly high volume was seen for the $450 strike put option expiring May 15, 2020, with 1,536 contracts trading so far today, representing approximately 153,600 underlying shares of BLK.  Below is a chart showing BLK's trailing twelve month trading history, with the $450 strike highlighted in orange:\n\nEND", "Adaptive Biotechnologies\u00a0(NASDAQ: ADPT) has begun a virtual clinical study to map the immune responses of people who have contracted COVID-19 or who are likely to have. Working with\u00a0Microsoft\u00a0(NASDAQ: MSFT),\u00a0Illumina\u00a0(NASDAQ: ILMN), and\u00a0LabCorp\u00a0(NYSE: LH), the biotech company is collecting blood samples from people in 24 U.S. cities that have been hard hit by the disease.Currently, there are two types of tests for COVID-19. The first are PCR (polymerase chain reaction) tests, which reveal whether a person is currently infected.\u00a0These tests are based on the DNA of the coronavirus, and all researchers need is a nose or throat swab from the patient to run them.The second type is a serology test: Using a sample of the patient's blood, this will look for the presence of specific antibodies that are generated by the immune system in response to SARS-CoV-2. Unlike a PCR test, serology tests will reveal people who have recovered from COVID-19 and no longer have active infections.END", "By Kirsty NeedhamSYDNEY, May 6 (Reuters) - Australia says its purchase of 10 million coronavirus test kits from Chinese genomics company BGI will not risk patient privacy, as researchers hope for greater price competition in a biotech market dominated by a U.S rival.The deal was struck even as relations between Australia and China have been strained by Australia's call for a global enquiry into the coronavirus outbreak, which China has framed as a U.S.-led attempt to blame it for the pandemic. BGI \u2013 Beijing Genomics Institute - has grown into one of the world's largest genomics companies in the two decades since it worked on the Human Genome Project. It has one lab in Australia and had been seeking to expand its genome sequencing services.BGI, whose BGI Genomics Co 300676.SZ is listed on the Shenzhen stock exchange, was named as having \"evident links\" to the Chinese government in a U.S. Trade Office report into Chinese technology transfer practices that was used to justify the U.S. imposition of tariffs on Chinese exports.END", "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF (Symbol: IBB) where we have detected an approximate $96.8 million dollar outflow -- that's a 1.2% decrease week over week (from 63,750,000 to 63,000,000).  Among the largest underlying components of IBB, in trading today Illumina Inc (Symbol: ILMN) is up about 1.9%, Alexion Pharmaceuticals Inc. (Symbol: ALXN) is up about 0.3%, and Incyte Corporation (Symbol: INCY) is lower by about 0.4%. For a complete list of holdings, visit the IBB Holdings page \u00bb \n\nThe chart below shows the one year price performance of IBB, versus its 200 day moving average:\n   \n\nEND", "END", "(RTTNews) - Illumina Inc. (ILMN) announced a profit for first quarter that dropped from last year.The company's bottom line came in at $173 million, or $1.17 per share.  This compares with $233 million, or $1.57 per share, in last year's first quarter.Excluding items, Illumina Inc. reported adjusted earnings of $243 million or $1.64 per share for the period. Analysts had expected the company to earn $1.25\t per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.END", "Investors in Illumina Inc (Symbol: ILMN) saw new options begin trading today, for the June 12th expiration.   At Stock Options Channel, our YieldBoost formula has looked up and down the ILMN options chain for the new June 12th contracts and identified one put and one call contract of particular interest.The put contract at the $315.00 strike price has a current bid of $14.10.  If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $315.00, but will also collect the premium, putting the cost basis of the shares at $300.90 (before broker commissions).  To an investor already interested in purchasing shares of ILMN, that could represent an attractive alternative to paying $317.88/share today.\n\nBecause the $315.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless.  The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 56%.  Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract.  Should the contract expire worthless, the premium would represent a 4.48% return on the cash commitment, or 38.00% annualized \u2014 at Stock Options Channel we call this the YieldBoost.\n\n\nBelow is a chart showing the trailing twelve month trading history for Illumina Inc, and highlighting in green where the $315.00 strike is located relative to that history:\n\nEND", "In this battle, we pit the global leader in the field of DNA sequencing against an up-and-coming biotech that uses the former's research tools to gain insights into the immune system. Both companies aim to give researchers and physicians greater information to make better diagnostic and treatment decisions. But which one shines as a better investment?END", "In this episode of Rule Breaker Investing, Motley Fool co-founder David Gardner and Motley Fool analysts Karl Thiel and Maria Gallagher review three Five-Stock Samplers. Learn about their businesses, why they went up or down, and what lessons you can take away from this review so that you can apply them to your future investments. Finally, get a sneak peek into what's coming next week and much more.To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.10 stocks we like better than\u00a0WalmartWhen investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*David and Tom just revealed what they believe are the\u00a0ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.END", "\nThere are 16 different analyst targets contributing to that average for Illumina Inc, but the average is just that \u2014 a mathematical average.  There are analysts with lower targets than the average, including one looking for a price of $220.00.  And then on the other side of the spectrum one analyst has a target as high as $370.00.  The standard deviation is $44.196.\n\n\nBut the whole reason to look at the average ILMN price target in the first place is to tap into a \"wisdom of crowds\" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes.  And so with ILMN crossing above that average target price of $313.00/share, investors in ILMN have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $313.00 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?  Below is a table showing the current thinking of the analysts that cover Illumina Inc:\n\n\nEND", "The coronavirus pandemic has made it clear that, despite all of the cutting-edge technologies in healthcare, there's still much that scientists don't know about how the human immune system works.\u00a0That's partly due to the complexity of biology and partly due to technical gaps. After all, scientists can only study what can be accurately measured -- and the diagnostic tools and sequencing processes required for quality research are still being invented and curated.\u00a0In recent years, the combination of machine learning and novel sequencing technologies has begun to remove those obstacles to knowledge and measurement. One company on the frontier is Adaptive Biotechnologies (NASDAQ: ADPT), which has wasted little time throwing its technology platform at the coronavirus pandemic. The stock has been a little volatile since its\u00a0initial public offering (IPO) in July 2019, but it still deserves a spot on your watch list.\u00a0END", "Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: http://tmsnrt.rs/2ggOmBiThe Morning News Call newsletter: http://tmsnrt.rs/2fwPLThU.S. stocks fell on Friday after President Donald Trump threatened to impose new tariffs on Beijing over the coronavirus crisis, while business warnings from Amazon.com and big oil firms highlighted the pain inflicted by global lockdowns .NAt 12:38 p.m.  ET, the Dow Jones Industrial Average .DJI was down 2.45% at 23,748.19. The S&P 500 .SPX was down 2.68% at 2,834.26 and the Nasdaq Composite .IXIC was down 3.35% at 8,591.362.   The top three S&P 500 .PG.INX percentage gainers:  ** Fortune Brands Home & Security Inc FBHS.N, up 6.1%  ** Clorox Co CLX.N, up 4.7%  ** Juniper Networks Inc  JNPR.N, up 2.8%   The top three S&P 500 .PL.INX percentage losers:  ** Weyerhaeuser Co WY.N, down 15.3%  ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 14.5%  ** Western Digital Corp WDC.OQ, down 13.2%   The top three NYSE .PG.N percentage gainers:  ** Vesper US Large Cap Short-Term Reversal Strategy UTRN.N, up 27.7%  ** John Hancock Multifactor Technology ETF JHMT.N, up 24.4%  ** North European Oil Royalty Trust NRT.N, up 20.2%   The top three NYSE .PL.N percentage losers:  ** Microsectors U.S. Big Oil Index 3x NRGU.N, down 21.6%  ** Mallinckrodt Plc MNK.N, down 19.2%  ** Oceaneering International Inc OII.N, down 19.1%   The top three Nasdaq .PG.O percentage gainers:  ** Discovery Inc DISCB.O, up 63.2%  ** Medigus Ltd MDGS.O, up 44.9%  ** International Money Express Inc IMXI.O, up 22%   The top three Nasdaq .PL.O percentage losers:  ** Delcath Systems Inc DCTH.O, down 43.5%  ** Pixelworks Inc PXLW.O, down 21.1%  ** Marlin Business Services Corp MRLN.O, down 20.9%    ** Wisdom Tree Investments Inc WETF.O: down 10.0%END", "END", "When a company develops products that should be game changers in the way cancer is treated, it's going to generate a lot of buzz. That's exactly what has happened for\u00a0Guardant Health (NASDAQ: GH).Helmy Eltoukhy and\u00a0AmirAli Talasaz founded Guardant Health in 2013 after both men served in various research positions at genomic sequencing pioneer Illumina. They set out to \"conquer cancer\" by tapping into the molecular information in tumor cells throughout all stages of cancer. And they've been successful so far.END", "The coronavirus pandemic has disrupted everyday life, altered the trajectory of the global economy, and reminded all of us not to be tricked by the thin veneer of civilization. For all of humanity's advanced technology, our best weapon against a fast-moving virus is to simply stay indoors and keep contact with others to a minimum.\u00a0While low-tech solutions can be pretty powerful against uncertainty, investors will gradually begin to chip away at the information gaps of the coronavirus pandemic. Can science provide answers and solutions before the end of 2020? How badly has the economy been damaged? How long will the economic recession last?\u00a0Partial answers to those questions will begin to emerge in April. That's why investors might want to keep a closer eye on electric utility holding company Xcel Energy (NASDAQ: XEL) and research and development collaborator Twist Bioscience (NASDAQ: TWST).\u00a0END", "Investors in Illumina Inc (Symbol: ILMN) saw new options begin trading this week, for the May 22nd expiration.   At Stock Options Channel, our YieldBoost formula has looked up and down the ILMN options chain for the new May 22nd contracts and identified one put and one call contract of particular interest.The put contract at the $267.50 strike price has a current bid of $14.70.  If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $267.50, but will also collect the premium, putting the cost basis of the shares at $252.80 (before broker commissions).  To an investor already interested in purchasing shares of ILMN, that could represent an attractive alternative to paying $283.07/share today.\n\nBecause the $267.50 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless.  The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 67%.  Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract.  Should the contract expire worthless, the premium would represent a 5.50% return on the cash commitment, or 44.57% annualized \u2014 at Stock Options Channel we call this the YieldBoost.\n\n\nBelow is a chart showing the trailing twelve month trading history for Illumina Inc, and highlighting in green where the $267.50 strike is located relative to that history:\n\nEND", "END", "Opportunities galore. That's the current status of the stock market as a result of the massive market meltdown caused by the coronavirus pandemic.Of course, not every stock that has plunged is a buy. Investors need to examine the pros and cons of any stock before scooping up shares, even if the stock appears to be more attractively valued than it's been in a long time.Illumina (NASDAQ: ILMN) is one of those stocks that now trade well below the highs from earlier this year. But should you buy this gene-sequencing stock during the coronavirus bear market?\u00a0END", "One of my favorite stocks right now is\u00a0Adaptive Biotechnologies\u00a0(NASDAQ: ADPT). You know how everybody and their mother is trying to find a cure for COVID-19? Here is how Adaptive is going about it: Instead of trying to decode this virus and understand its RNA, Adaptive is focusing on humans' immune response to it.\u00a0How is it that some people can catch COVID-19 and have no symptoms? Adaptive wants to solve that mystery. And the company believes that if it can figure out how an immune system successfully responds to this virus, it will help us detect COVID-19, treat it, and maybe even provide a cure.\u00a0END", "In trading on Thursday, shares of Illumina Inc (Symbol: ILMN) crossed above their 200 day moving average of $299.79, changing hands as high as $300.64 per share.  Illumina Inc shares are currently trading up about 1.6% on the day.  The chart below shows the one year performance of ILMN shares, versus its 200 day moving average:\n\n   END", "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF (Symbol: IBB) where we have detected an approximate $277.5 million dollar outflow -- that's a 4.1% decrease week over week (from 62,100,000 to 59,550,000).  Among the largest underlying components of IBB, in trading today Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 1.4%, Biogen Inc (Symbol: BIIB) is trading flat, and Illumina Inc (Symbol: ILMN) is lower by about 1%. For a complete list of holdings, visit the IBB Holdings page \u00bb \n\nThe chart below shows the one year price performance of IBB, versus its 200 day moving average:\n   \n\nEND", "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology ETF (Symbol: IBB) where we have detected an approximate $240.2 million dollar inflow -- that's a 4.1% increase week over week in outstanding units (from 59,650,000 to 62,100,000).  Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is off about 0.5%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 5.4%, and Illumina Inc (Symbol: ILMN) is up by about 2.4%. For a complete list of holdings, visit the IBB Holdings page \u00bb \n\nThe chart below shows the one year price performance of IBB, versus its 200 day moving average:\n   \n\nEND", "The number of people diagnosed with COVID-19 continues to grow rapidly around the world, and while many companies are working on potential treatments and vaccines, there are still no approved therapies. With that said, it is worth noting that efforts to fight the novel coronavirus across a range of technologies continue to ramp up.\u00a0END", "Health care, which makes up nearly 18% of American GDP, has long been a fruitful hunting ground for investors seeking growth. And medical-tech and medical-device stocks have always been particularly compelling niches.Not only do these companies ride the coattails of inexorable health-care spending, but their commitment to research and development can create new industries that they can in turn dominate.It's not an easy time right now, of course. The COVID-19 outbreak has taken a chunk out of every sector and almost every industry, with only a few \"coronavirus stocks\" enjoying any meaningful gains. Medical devices have at least been better than the market, which has declined by about 29% in this bear market so far, as measured by the S&P 500. But the iShares U.S. Medical Devices ETF (IHI) still has been cut to the tune of 25% in the same time frame.That could provide investors with a chance to buy medical-device stocks and other med-tech plays at a significant discount, however. While their growth might be stunted in the short-term, their longer-term prospects are likely to improve again once the COVID-19 threat is contained - and a few are seeing additional business in the wake of the outbreak.END", "Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Illumina Inc (Symbol: ILMN), where a total of 8,062 contracts have traded so far, representing approximately 806,200 underlying shares.  That amounts to about 53.1% of ILMN's average daily trading volume over the past month of 1.5 million shares.  Especially high volume was seen for the $300 strike call option expiring September 18, 2020, with 5,012 contracts trading so far today, representing approximately 501,200 underlying shares of ILMN.  Below is a chart showing ILMN's trailing twelve month trading history, with the $300 strike highlighted in orange:\n\nEND", "Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful.  One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.  A stock is considered to be oversold if the RSI reading falls below 30.\n\nIn trading on Thursday, shares of Illumina Inc (Symbol: ILMN) entered into oversold territory, hitting an RSI reading of 27.2, after changing hands as low as $222.32 per share.  By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 27.7.  A bullish investor could look at ILMN's 27.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.    The chart below shows the one year performance of ILMN shares:\n   \n   END", "Investors in Illumina Inc (Symbol: ILMN) saw new options begin trading this week, for the April 9th expiration.   At Stock Options Channel, our YieldBoost formula has looked up and down the ILMN options chain for the new April 9th contracts and identified one put and one call contract of particular interest.The put contract at the $270.00 strike price has a current bid of $11.70.  If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $270.00, but will also collect the premium, putting the cost basis of the shares at $258.30 (before broker commissions).  To an investor already interested in purchasing shares of ILMN, that could represent an attractive alternative to paying $272.64/share today.\n\nBecause the $270.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless.  The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 56%.  Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract.  Should the contract expire worthless, the premium would represent a 4.33% return on the cash commitment, or 46.58% annualized \u2014 at Stock Options Channel we call this the YieldBoost.\n\n\nBelow is a chart showing the trailing twelve month trading history for Illumina Inc, and highlighting in green where the $270.00 strike is located relative to that history:\n\nEND", "The widening coronavirus outbreak has been weighing on medical device companies amid concern the current crisis will interrupt use or orders of their products.Here, let's talk about two companies -- one that is seeing an impact and one that hasn't so far. Do I like one better than the other? No. Both are trading at bargain prices and make great long-term investments due to their growth prospects.END", "The stock market is starting off 2020 with a bang, but investors in\u00a0Illumina (NASDAQ: ILMN) haven't shared in those gains. Despite strong performances by companies in technology, biotech, and the healthcare sector as a whole, Illumina's shares are down 10% since the beginning of the year after the gene-sequencing leader reported better-than-expected results for the fourth quarter and announcing an innovative new line of sequencing systems.Should Illumina investors expect more of the same lackluster performance in 2020? The market seems to think that the year ahead will be unspectacular for this leading healthcare company, but let's look at where the company will be 12 months from now, when investors and analysts will be looking ahead to 2021.END", "As Illumina (NASDAQ: ILMN) moves more into the clinical diagnosis space, the DNA-sequencing specialist has made a big addition to its board of directors: Scott Gottlieb, a former commissioner of the Food and Drug Administration. Gottlieb is currently a special partner at the venture capital firm New Enterprise Associates as well as a resident fellow at\u00a0 the American Enterprise Institute, a public policy think tank.END", "DNA sequencing giant Illumina (NASDAQ: ILMN) started 2020 off with what many might consider disappointing news, announcing that it had dropped\u00a0the planned acquisition of Pacific Biosciences (NASDAQ: PACB). That followed a lackluster year for Illumina's shares, which took a 19% hit in July \u00a0as the company reported\u00a0lower-than-expected revenue in the second quarter.But recent news should give investors reason to take a look at Illumina shares. The company reported fourth-quarter earnings that topped estimates, announced a collaboration agreement with Roche (OTC: RHHBY), and launched two new sequencing systems.END", "END", "For 17 years, a popular TV game show asked a question that was easy to answer. The question was in the game show's name itself: Who Wants to Be a Millionaire?\u00a0Obviously, the answer to the question is \"pretty much everyone.\" The hard part was answering the show's other questions. It took 12 correct answers to win the $1 million prize.Are there easier ways to become a millionaire? Sure. Buying the right stock and holding it for enough time can amass a fortune for patient investors. The trick is finding that right stock.There are plenty of stocks that are pretty good candidates. One that I really like is Guardant Health (NASDAQ: GH). But could Guardant Health actually be a millionaire-maker?END", "Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful.  One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.  A stock is considered to be oversold if the RSI reading falls below 30.\n\nIn trading on Thursday, shares of Illumina Inc (Symbol: ILMN) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $295.25 per share.  By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 56.2.  A bullish investor could look at ILMN's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.    The chart below shows the one year performance of ILMN shares:\n   \n   END", "The worst performing sector as of midday Thursday is the Healthcare sector, showing a 2.2% loss.  Within that group, Wellcare Health Plans Inc (Symbol: WCG) and Illumina Inc (Symbol: ILMN) are two of the day's laggards, showing a loss of 42.8% and 5.1%, respectively.  Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 1.3% on the day, and down 1.24% year-to-date.  Wellcare Health Plans Inc, meanwhile, is up 5.97% year-to-date, and Illumina Inc, is down 10.35% year-to-date.  Combined, WCG and ILMN make up approximately 1.7% of the underlying holdings of XLV.\n\nThe next worst performing sector is the Materials sector, showing a 1.6% loss.  Among large Materials stocks, DuPont (Symbol: DD) and Packaging Corp of America (Symbol: PKG) are the most notable, showing a loss of 8.6% and 6.0%, respectively.  One ETF closely tracking Materials stocks is the Materials Select Sector SPDR ETF (XLB), which is down 1.5% in midday trading, and down 4.90% on a year-to-date basis.  DuPont, meanwhile, is down 17.83% year-to-date, and Packaging Corp of America, is down 11.88% year-to-date.  Combined, DD and PKG make up approximately 8.8% of the underlying holdings of XLB.\n\nComparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:\n\n\n \n\n\n\n\nEND", "The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.KENNEDY-WILSON HOLDINGS INC (KW) is a mid-cap value stock in the Real Estate Operations industry. The rating according to our strategy based on Peter Lynch changed from 69% to 74% based on the firm\u2019s underlying fundamentals and the stock\u2019s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.Company Description: Kennedy-Wilson Holdings, Inc. is a real estate investment company. The Company owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on commercial properties located in the Western United States, the United Kingdom, Ireland, Spain, Italy and Japan. The Company also provides real estate services primarily to financial services clients. The Company's segments include KW Investments, and KW Investment Management and Real Estate Services (IMRES). KW Investments invests in residential and commercial properties, as well as loans secured by real estate. IMRES provides real estate-related services to investors and lenders, with a focus on financial institution-based clients. As of December 31, 2017, the Company had an ownership interest in approximately 53.1 million square feet of property globally.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.END", "A few days ago, I predicted that there would be few if any surprises with Illumina's (NASDAQ: ILMN) fourth-quarter results. This was an easy prediction to make: Illumina CEO Francis deSouza's presentation at the J.P. Morgan Healthcare Conference earlier this month included some sneak peeks at the company's Q4 performance.Illumina announced its Q4 results after the market closed on Wednesday. I was right that there wouldn't be many surprises. But there was one twist. Here are the three most important things to know about Illumina's Q4 results.END"]}